Form 4: Avalo Therapeutics CFO Christopher Ryan Sullivan Awarded Stock Options and Restricted Stock Units

Christopher Ryan Sullivan, CFO of Avalo Therapeutics, Inc., received stock options and restricted stock units on August 13, 2024.

Summary

• Christopher Ryan Sullivan, the Chief Financial Officer of Avalo Therapeutics, Inc., was granted stock options and restricted stock units (RSUs) on August 13, 2024.
• The stock option grants Sullivan the right to buy 186,700 shares of common stock at an exercise price of $9.88 per share.
• These options vest 25% on March 28, 2025, and then 1/36 monthly thereafter, contingent upon Sullivan's continued service.
• Sullivan also received 72,600 RSUs, each representing a contingent right to receive one share of common stock upon vesting.
• The RSUs vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, also subject to continued service.
• The filing also notes that the amount of beneficial securities owned in Table I has been adjusted to reflect a 1-for-240 reverse stock split on December 28, 2023.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting the grant of stock options and RSUs. However, the fact that the company is granting equity suggests a degree of confidence in its future prospects, hence the slightly positive sentiment.

Positives

• The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules for both the options and RSUs encourage long-term commitment from the CFO.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Avalo Therapeutics' stock, which is subject to market risks and company-specific factors.
• If the CFO leaves the company before the options and RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and, implicitly, growth.

Industry Context

Granting stock options and RSUs to executives is a common practice in the biotechnology industry to incentivize performance and retain key personnel. The specific terms of the grants (vesting schedule, exercise price) are tailored to the company's specific circumstances and strategic goals.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation tools in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use similar equity-based compensation to align executive incentives with shareholder value.
• The vesting schedules (25% after one year, then monthly for options; annual for RSUs) are fairly typical, designed to encourage long-term commitment.
• The exercise price of $9.88 for the options will only provide value to the recipient if the share price increases above this level.

Stakeholder Impact

• Shareholders may view the equity grants positively, as they align management's interests with increasing shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership team.
• The grants have no immediate impact on customers, suppliers, or creditors.

Key Dates